Interstitial Lung Disease (ILD) Program
Interstitial lung diseases (ILD) are difficult to diagnose and treat. At Yale, we have the expertise and experience needed to treat all forms of ILD, including idiopathic pulmonary fibrosis (IPF), interstitial lung diseases associated with autoimmune disorders, occupational lung disease, and sarcoidosis. Our program, led by pulmonologists, is an internationally recognized center of excellence.
Our team can offer patients expertise and support in multiple areas, including treatment of complex lung diseases, the opportunity to participate in clinical and translational studies, and the chance to receive experimental therapy. We also work tirelessly to conduct research into the causes and potential cures for ILD and participate in the education and support of patients, providers, and caregivers. Through our multidisciplinary program, our pulmonologists with expertise in ILD collaborate with specialty-trained pulmonary pathologists, chest radiologists, rheumatologists, and occupational medicine physicians.
As members of the Pulmonary Fibrosis Foundation Clinical Care Network and through Yale’s work with the Scleroderma Foundation, we collaborate with physicians across the country to provide outstanding care to patients with all forms of ILD with a special focus on idiopathic pulmonary fibrosis and Scleroderma-associated interstitial lung disease (SSc-ILD).
We will formulate a treatment plan based on the specific diagnosis, medical issues, and preferences. We will also keep patients’ referring and primary care doctors informed of our recommendations. We also offer strong support from the pulmonary fibrosis community at the local and national level. Locally, we conduct periodic support groups for patients with IPF and scleroderma.